Beeline Medicines
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Clarendon St, Boston, Massachusetts,...Website
www.beelinemedicines.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Beeline Medicines
Beeline Medicines is a clinical-stage biotechnology company headquartered in Stamford, Connecticut, with operations in Boston, Massachusetts. Founded in July 2025 and publicly debuted in April 2026, the company is focused on developing precision therapies for autoimmune and inflammatory diseases, targeting the underlying drivers of immune dysfunction rather than symptom management alone. Its pipeline consists of five programs in-licensed from Bristol Myers Squibb, including afimetoran, a once-daily oral small-molecule TLR7/TLR8 inhibitor in Phase 2 development for lupus, as well as candidates in development for atopic dermatitis, plaque psoriasis, and other immune-mediated conditions. The company also has two preclinical next-generation biologics targeting the IL-10 and IL-18 pathways advancing toward first-in-human studies. Beeline Medicines is backed by a $300 million Series A financing led by Bain Capital and is led by a management team with prior experience at SpringWorks TherapeutRead more
Beeline Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Beeline Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Beeline Medicines had a recent Job posting/layoffs
Earning: See what the market has to say on Beeline Medicines recently announced quarterly report
Product Launch: Get notified when Beeline Medicines launches new products
Funding: Get notified immidiatlly once Beeline Medicines has new funding data
Beeline Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Beeline Medicines has recently received funding, and reach out quickly before it becomes old news!
Check out if Beeline Medicines is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Beeline Medicines
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Beeline Medicines as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Beeline Medicines is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Beeline Medicines is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Beeline Medicines.
Beeline Medicines financials insights
Gather financial insights about Beeline Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series A
$126.3M
Beeline Medicines Tech Stack
A closer look at the technologies used by Beeline Medicines
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Beeline Medicines News & Media
Beeline Medicines Announces Upsized Series A of $426.3 Million to Advance Category-Leading Autoimmune and Inflammatory Disease Portfolio
– $126.3 million of new funding adds to previously announced $300 million Series A financing –
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Beeline Medicines
Sign Up For FreeTo access detailed company insights
Beeline Medicines is a clinical-stage biotechnology company headquartered in Stamford, Connecticut, with operations in Boston, Massachusetts. Founded in July 2025 and publicly debuted in April 2026, the company is focused on developing precision therapies for autoimmune and inflammatory diseases, targeting the underlying drivers of immune dysfuncti... Read More
